3-甲基-4-氨基-5-乙氧羰基甲硫基三唑席夫碱的合成及生物活性

以3-甲基-4-氨基-5-巯基-1,2,4-三唑为原料,在乙醇/氢氧化钠体系中与氯乙酸乙酯反应合成了3-甲基-4-氨基-5-乙氧羰基甲硫基-1,2,4-三唑,再与取代芳醛合成了6种(A1～A6)新型乙氧羰基三唑席夫碱化合物,化合物结构经元素分析,IR,1H NMR,MS等确证。对烟草赤星病、马铃薯干腐病、小麦赤霉病、西瓜枯萎病4种植物病原菌的初步生物活性测试结果表明,化合物A3的抑菌活性优于或相当于对照原药三唑酮。     

新型5-甲基-1,2,4-三唑-3-硫酮类化合物的合成及抗菌活性研究

利用生物活性叠加原理,以4-氨基-5-甲基-1,2,4-三唑-3-硫酮为原料,设计合成了15个未见报道的化合物2-N-2′,3′,4′,6′-四-O-乙酰基-β-D-吡喃葡萄糖基-4-N-取代苯基亚胺基-5-甲基-1,2,4-三唑(2a～2e),4-N-取代苄基氨基-5-甲基-1,2,4-三唑(3a～3e)和2-N-2′,3′,4′,6′-四-O-乙酰基-β-D-吡喃葡萄糖基-4-N-取代苄基氨基-5-甲基-1,2,4-三唑(4a～4e).其结构经IR,1H NMR,13C NMR和元素分析确认.生物活性测试表明,所有化合物均表现出一定的抑菌活性,尤其是化合物4b对大肠杆菌和金黄色葡萄球菌的最小抑菌浓度为8μg/mL,明显优于市售抗菌药物氟康唑,表现出较强的抗细菌活性;同时,与三氯生相比,所有化合物对白色念珠菌的最小抑菌浓度(MIC)均小于或等于32μg/mL,亦表现出较好的抗真菌活性.     

微波辐射合成2-乙氧羰基甲硫基-4-取代苯基亚氨基-4H-1-萘酮类化合物

以对取代苯胺与2-乙氧羰基甲硫基-1,4-萘醌为底物,采用微波合成法合成了3个新型的蛋白酶体抑制剂的关键中间体——2-乙氧羰基甲硫基-4-苯基亚氨基-4H-1-萘酮类化合物(3a~3c),其结构经1H NMR和1D NOE表征。在最佳反应条件[THF为溶剂,TiCl4为催化剂,于60℃微波(240 W)反应15 min]下,2-乙氧羰基甲硫基-4-(4-硝基苯基)亚氨基-4H-1-萘酮(3a)的收率84.2%。     

含吡唑1,2,4-三唑噻二嗪衍生物的合成及抑菌活性

1-苯基-3-甲基-5-氯-4-吡唑甲醛与4-氨基-5-取代苯基-1,2,4-三唑-3-硫酮缩合生成4-(1-苯基-3-甲基-5-氯吡唑次甲亚胺基)-5-(取代苯基)-2H-1,2,4-三唑-3(4H)-硫酮,再烷基加成化为新型含吡唑基5,6-2H-1,2,4-三唑[3,4-b][1,3,4]噻二嗪衍生物。 化合物结构经¹H NMR、IR以及元素分析确认。 初步生物活性测试结果表明,在100 mg/L浓度下,化合物8a(3-(2-甲基苯基)-6-(5-氯-2-甲基-4-苯基吡唑)-7-(4-硝基苯基)-5H-1,2,4-三唑[3,4-b][1,3,4]噻二嗪)对黄瓜炭疽病的抑制率达90%。     

7-取代三唑硫乙氧基黄酮衍生物的合成及生物活性

7-羟基黄酮与过量1,2-二溴乙烷反应得到7-溴乙氧基黄酮,将其分别与3-取代-4-氨基-1,2,4-三唑-5-硫酮肉桂醛席夫碱、3-取代-4-苯基-5-巯基-1,2,4-三唑、3-(α-萘亚甲基)-5-巯基-1,2,4-三唑及3-巯基-5-氨基-1,2,4-三唑肉桂醛席夫碱反应,得到4类共16个7-三唑硫乙氧基黄酮类衍生物.采用红外光谱(IR)、核磁共振氢谱(1H NMR)、质谱(MS)及元素分析(EA)等方法对化合物的结构进行了确证.测定了目标化合物清除超氧自由基(O-·2)、羟自由基(·OH)和2,2-二苯基-1-苦味酰基自由基(DPPH·)的活性及总还原能力,并测定了其抗菌活性.结果表明,多数化合物在0.5 mg/m L浓度时具有抗DPPH·活性,其中7-(5-苯亚甲基-4-苯基烯丙亚胺基-1,2,4-三唑-3-硫乙氧基)黄酮(1i)活性较强;多数化合物表现了较好的抑菌活性,其中7-(5-苯亚甲基-4-苯基-1,2,4-三唑-3-硫乙氧基)黄酮(2c)对大肠杆菌、金黄色葡萄球菌和黑曲霉均具有较强的抑制作用.     

N-(5-对-氯苯氧甲基-1,3,4-噻二唑-2-基)-S-(4-苯基-5-苯氧甲基-1,2,4-三唑-3-基)乙酰胺的合成与表征

取代苯氧乙酰肼(1a～1c)与异硫氰酸芳基酯(2a～2d)反应得到酰基硫脲类化合物(3a～3l),经碱合环得到4-苯基-5-苯氧甲基-1,2,4-三唑-3-硫酮(4a～4l),然后再与N-(5-对氯苯氧甲基-1,3,4-噻二唑-2-基)氯乙酰胺(6)反应合成了化合物N-(5-对氯苯氧甲基-1,3,4-噻二唑-2-基)-S-(4-苯基-5-苯氧甲基-1,2,4-三唑-3-基)乙酰胺(7a～7l)。所有化合物结构经元素分析、IR、1HNMR和MS确证。测定了化合物4e的晶体结构,其属于三斜晶系,P-1空间群,晶胞参数a=7.123(4),b=9.786(5),c=11.543(6),α=70.846(7)°,β=80.089(9)°,γ=89.922(11)°,V=747.5(7)3,Dc=1.345g/cm3,Z=2,F(000)=310,μ=0.218mm-1,R=0.0913,wR=0.2622     

新型含2,4-二氯苯基-1,2,4-三唑Schiff碱Mannich碱衍生物的合成及生物活性

3-巯基-4-氨基-5-(2,4-二氯)苯基-1,2,4-三唑与取代苯甲醛经缩合反应制得中间体4-(取代苯次甲亚胺基)-5-(2,4-二氯苯基)-4H-1,2,4-三唑-3-硫酮(3a~3d);3a~3d在甲醛溶液中分别与吗啉于75℃反应4 h合成了4个新型的含2,4-二氯苯基均三氮唑Schiff碱Mannich碱衍生物——4-(取代苯甲亚胺基)-5-(2,4-二氯苯基)-2-(吗啉亚甲基)-2H-1,2,4-三唑-3-硫酮,收率69%~81%,其结构经1H NMR,13C NMR,IR及元素分析表征。初步生物活性测试结果表明:部分目标化合物在用药量为100 mg·L-1时对黄瓜霜霉病的抑制率达100%。     

3-（5-H/CH3-苯并咪唑-2-亚甲硫基）-5-取代-[1,2,4]三唑-4-胺衍生物的合成、结构和生物活性

利用3-巯基-4-氨基-5-取代-1,2,4-三唑和2-氯甲基-5-取代-苯并咪唑在氢氧化钠溶液中反应,得到17个3-(5-H/CH3-苯并咪唑-2-亚甲硫基)-5-取代-[1,2,4]三唑-4-胺衍生物.所有目标化合物经元素分析、红外光谱、核磁共振氢谱确定结构;采用溶液法得到化合物3f与Co2+形成的配合物,通过X射线单晶衍射确定结构.初步的生物活性测试结果表明,所合成的化合物对小麦芽鞘和绿豆发芽有着较好的生长调节作用;化合物3d,3i对金黄色葡萄球菌具有一定的抑制作用.     

4-取代苯次甲亚胺-5-(1-苯基-3-甲基-5-氯吡唑)-2H-1,2,4-三唑-3-硫酮的合成

以乙醇为溶剂,冰醋酸为催化剂,4-氨基-5-(1-苯基-3-甲基-5-氯吡唑)-1,2,4-三唑-3-硫酮(1)与芳醛经缩合反应合成了7个新型的4-取代苯次甲亚胺-5-(1-苯基-3-甲基-5-氯吡唑)-4H-1,2,4-三唑-3-硫酮(3a~3g),收率66%~74%,其结构经1H NMR,IR及元素分析表征。合成4-(苯次甲亚胺)-5-(1-苯基-3-甲基-5-氯吡唑)-2H-1,2,4-三唑-3-硫酮(3a)的最佳反应条件为:以乙醇为溶剂,乙酸为催化剂,1 10 mmol,n(苯甲醛)∶n(1)=1.2,于75℃反应3 h,产率74%。     

2,2-二甲基-5-取代苯基-3-(1,2,4-三唑-1/4-甲基)-3-戊醇类化合物的合成、表征及生物活性

取代苯甲醛经缩合、催化氢化、环氧化和开环反应合成了9种2,2-二甲基-5-取代苯基-3-(1,2,4-三唑-1-基甲基)-3-戊醇类化合物和2种2,2-二甲基-5-取代苯基-3-(1,2,4-三唑-4-基甲基)-3-戊醇类新化合物. 并对1,2,4-三唑-1-基衍生物和1,2,4-三唑-4-基衍生物的选择性合成进行了研究; 新化合物结构经质谱, ¹H NMR, 元素分析等确证, 并用单晶X射线衍射测定了化合物1a的晶体结构. 生物活性测试结果表明, 部分化合物具有强杀菌活性.     

新型含取代哌嗪的5-(吡啶-3-基)-1,2,4-三唑Mannich碱和双Mannich碱的合成及生物活性

根据药物分子设计的活性基团组合原理,通过在1,2,4-三唑环的5位引入吡啶基,同时在4位芳基亚甲氨基的苯环上引入氟或三氟甲基,设计合成了一系列含氟、吡啶和哌嗪基团的1,2,4-三唑Mannich碱和双Mannich碱类化合物.通过核磁共振氢谱(~1H NMR)、碳谱(~(13)C NMR)和元素分析确证了目标化合物的结构.生物活性测试结果表明,部分化合物对油菜具有一定的除草活性;化合物2a,2d和2f(50 mg/L)对苹果轮纹病菌表现出较好的抑制活性,与对照药三唑酮活性相当;化合物2a,2b,2d和2i(180 mg/L)对酮醇酸还原异构酶(KARI酶)表现出了显著的离体抑制活性(抑制率51.7%~88.7%).     

3-(N-取代苯基-2-乙酰胺基)硫基-4-N-取代邻羟苯基亚胺基-5-甲基-1,2,4-三唑类化合物的合成及生物活性研究

以对称二氨基硫脲为原料,与冰醋酸反应生成5-甲基-4-氨基-1,2,4-三唑-3-硫酮(1);在弱酸性条件下,1与取代水杨醛反应生成席夫碱中间体5-甲基-4-(N-取代邻羟苯基)亚胺基-1,2,4-三唑-3-硫酮(2a～2c);最后在碱性条件下分别与N-取代苯基-2-氯乙酰胺发生烷基化反应生成15种未见报道的目标化合物3-(N-取代苯基-2-乙酰胺基)硫基-4-(N-取代邻羟苯基)亚胺基-5-甲基-1,2,4-三唑(3a～3o),其结构经IR,1H NMR,13C NMR确证.初步生物测试表明,质量分数为0.01%时,3a～3o对白色念珠菌的抑菌率均达90%以上,具有很强的抑菌活性;对金黄色葡萄球菌、大肠杆菌的抑菌率达80%以上,具有较强的抑菌活性.     

Synthesis and Crystal Structure of 3,6-Bis（4-methyl-1,2,3-thiadiazol-5-yl）-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole

The compound 3,6-bis(4-methyl-1,2,3-thiadiazol-5-yl)-1,2,4-triazolo[3,4-b][1,3,4] thiadiazole(C9H6N8S3,Mr = 322.40) has been synthesized by the reaction of 4-amino-3-(4-methyl-1,2,3-thiadiazolyl)-5-mercapto-1,2,4-triazole with 4-methyl-1,2,3-thiadiazol-5-carboxylic acid and phosphorus oxychloride,and its structure was characterized by IR,1H NMR,EI-MS,elemental analysis and single-crystal X-ray diffraction.The crystal of the title compound belongs to monoclinic,space group C2/c with a = 2.0053(4),b = 1.3081(3),c = 1.0556(2) nm,β = 112.69(3)°,Z = 4,V = 2.5548(9) nm3,Dc = 1.676 g/cm3,μ = 0.582 mm-1,F(000) = 1312,R = 0.0546 and wR = 0.1523.X-ray analysis indicates that all rings are essentially planar in this molecule,and an intermolecular hydrogen bond C(9)-H(9)…N(2) and weak intramolecular interactions between S(1)…N(7),S(3)…N(1) and S(2)…N(4) are observed.     

新型S(N)-β-D-葡萄糖苷-4-N-(取代邻羟苯基)亚胺基-5-(4-甲基-1,2,3-噻二唑)-1,2,4-三唑的合成及生物活性

在KOH/acetone体系中,4-N-(取代邻羟苯基)亚胺基-5-(4-甲基-1,2,3-噻二唑)-1,2,4-三唑-3-硫酮(3a～3d)与溴-α-D-四乙酰葡萄糖发生Kenigs-Knorr反应,合成了8个未见报道的S(N)-β-D-乙酰葡萄糖苷,其结构经1H NMR、13C NMR、红外光谱及元素分析等确定.目标化合物的生物活性测试结果表明,它们对金黄色葡萄球菌、白色念珠菌和大肠杆菌均显示了较好的抑菌活性,其效果接近或优于对照药物三氯生和氟康唑的抑菌效能.其中,化合物2-N-(2’,3’,4’,6’-O-四乙酰基-β-D-吡喃葡萄糖基)-4-N-(3,5-二溴邻羟苯基)亚胺基-5-(4-甲基-1,2,3-噻二唑)-1,2,4-三唑-3-硫酮(4d)及3-S-(2’,3’,4’,6’-O-四乙酰基-β-D-吡喃葡萄糖硫基)-4-N-(3,5-二溴邻羟苯基)亚胺基-5-(4-甲基-1,2,3-噻二唑)-1,2,4-三唑(5d)具有较强的抑菌活性.     

3-甲基-4-对甲苯基-5-(2-吡啶基)-1，2，4-三唑-铜(Ⅱ)配合物

A copper(Ⅱ) complex [CuL(H₂O)(Sal)]·0.5H₂O was obtained by the reaction of copper(Ⅱ) salicylate with 3-methyl-4-(4-methylphenyl)-5-(2-pyridyl)-1,2,4-triazole (L) in ethanol-water solution at room temperature. The crystal belongs to triclinic system with space group P1, and a=0.913 6(4) nm, b=1.122 2(5) nm, c=1.263 3(7) nm, α=67.10(2)°, β=76.31(3)°, γ=68.17(2)°, V= 1.101(1) nm³, Z=2. The final refinement gave R₁=0.039 8 and wR₂=0.106 0 for 3 453 reflections with I>2σ(I). This complex is a good purple fluorescent material in solid state at room temperat-ure. CCDC: 685713.     

Syntheses of substituted-1,2,4-triazoles

Starting from the readily available 3-phenylpropionitrile, 3-(or 5-)(2-phenethyl)-1,2,4-triazole 3 was prepared. Reaction of compounds 3 with diazomethane afforded 1-methyl-3-(2-phenethyl)-1,2,4-triazole (4) and 1-methyl-5-(2-phenethyl)-1,2,4-triazole (5) . Reaction of compound 3 with methanesulfonyl chloride, benzenesulfonyl chloride or p-toluenesulfonyl chloride afforded only one of the expected isomer; namely compounds 6 , 7 and 8 respectively.     

Synthesis, spectral characterization and biological activity of zinc(II) complexes with 3-substituted phenyl-4-amino-5-hydrazino-1, 2, 4-triazole Schiff bases

New Zn(II) complexes have been synthesized by the reactions of zinc(II) acetate with Schiff bases derived from 3-substituted phenyl-4-amino-5-hydrazino-1, 2, 4-triazole and benzaldehyde, 2-hydroxyacetophenone or indoline-2,3-dione. All these complexes are soluble in DMF and DMSO; low molar conductance values indicate that they are non-electrolytes. Elemental analyses suggest that the complexes have 1:1 stoichiometry of the type [ZnL(H(2)O)(2)], [ZnL'(OAc)(2)(H(2)O)(2)] (L=dianionic Schiff bases derived from 3-(substituted phenyl)-4-amino-5-hydrazino-1, 2, 4-triazole and 2-hydroxyacetophenone or indoline-2,3-dione; L'=neutral Schiff bases derived from 3-(substituted phenyl)-4-amino-5-hydrazino-1, 2, 4-triazole and benzaldehyde) and they were characterized by FT-IR, (1)H NMR, (13)C NMR and FAB mass. All these Schiff bases and their complexes have also been screened for their antibacterial activities against Bacillus subtilis, Escherichia coli and antifungal activities against Colletotrichum falcatum, Aspergillus niger, Fusarium oxysporium and Carvularia pallescence by petriplates methods.     

Synthesis and study of heteroaromatic ligands containing a pyrimidine ring

5-Hexyl-3-[2-(1H-pyrazol-1-yl)pyrimidin-4-yl]amino-1(2)H-1,2,4-triazoles and 2-(3,5-dipropyl-4-ethyl-1H-pyrazol-1-yl)-6-methyl-4-(5-methyl-1H-pyrazol-1-yl)-aminopyrimidine were synthesized by the reaction of 4-chloropyrimidines with 3-araino-5-hexyl-1H-1,2,4-triazole and 3-amino-5-methyl-1H-pyrazole. Their IR, UV, and PMR spectra were investigated. New methods for the preparation of the intermediates, viz., 2-hydrazino-4(3H)-pyrimidinones and 2-(1H-pyrazol-1-yl)-4(3H)-pyrimidinones, that make it possible to obtain these compounds in higher yields are described.Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 12, pp. 1673–1677, December, 1980.     

Hydrothermal Synthesis and Structural Characterization of Three-dimensional Metal-organic Framework [Zn3（C2H2N3）2（C7H5O2）4]

Hydrothermal reaction between mixed ligand(1,2,4-triazole and benzoic acid) and Zn(NO3)2·6H2O afforded a three-dimensional(3D) metal-organic framework Zn3(C2H2N3)2(C7H5O2)4(C2H2N3=1,2,4-triazole,C7H5O2=benzoic acid).The compound was crystallized in the hexagonal system with space group R3:a=2.90234(9) nm,b=2.90234(9) nm,c=1.08597(5) nm,γ=120°,V=7.9222(5) nm3,Mr=816.68,Dc=1.541 g/cm3,Z=9,F(000)=3708,R=0.0636,and wR=0.1777.Its structure consists of ZnN2O2 tetrahedron and ZnN2O4 octahedron,which are connected ...